The role of alendronate in mitigating perimenopausal bone loss: a double-blind randomized controlled pilot study.
Compared with placebo, alendronate treatment resulted in a significant protection against bone loss in healthy perimenopausal women. This protection occurred at both the spine and the hip and was evident after 6 months of therapy.
Mersereau
Jennifer E
JE
Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco, California, USA. jmerse@med.unc.edu
Khouri
Claire
C
Jaffe
Robert B
RB
D019386:Alendronate / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D016723:Bone Remodeling / Q000187:drug effects / Q000502:physiology; D004311:Double-Blind Method; D005260:Female; D006615:Hip; D006801:Humans; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy*; D010865:Pilot Projects; D010919:Placebos; D013131:Spine; D013997:Time Factors
D050071:Bone Density Conservation Agents; D010919:Placebos; D019386:Alendronate